Recently, Meinian Health (002044. SZ) released its 2026 semi annual report, which showed that its operating revenue in the first half of 2026 was 3.844 billion yuan, of which the revenue obtained by combining AI technology in its main revenue exceeded 218 million yuan. The physical examination industry has strong seasonal characteristics. In the traditional off-season of the first half of the year, due to the distribution of holidays and the financial accounting cycle of enterprises and institutions, some enterprises have delayed their budgets and inspections. Meinian Health stated that the overall order signing of the company is relatively stable, and the business affected by the inspection pace will gradually be released in the second half of the year.

As a leading player in domestic "AI+health management", Meinian Health continues to use technological innovation as its core engine, deeply empowering medical core scenarios with AI, deeply embedding diagnosis, quality control, and service processes, and helping to improve doctors' diagnostic efficiency and accuracy. In the first half of this year, the "Healthy Xiaomei" AI intelligent main inspection system has covered 394 physical examination centers, reviewed and generated over 16 million physical examination reports, and continuously optimized the efficiency and quality consistency of report issuance; The ultrasound AI voice intelligent agent has been launched in 224 physical examination centers, effectively reducing the average examination time and report writing time.

At the same time, Meinian Health continues to improve its cancer "early screening and testing" product matrix, promoting mature products such as colon cancer fecal DNA methylation, cervical cancer E6/E7, lung cancer Ning, capsule gastroscopy, etc. It continues to launch innovative products such as lung cancer methylation, "Lung Chang'an", and AI aging assessment product "Yan Ling'an Biological Age Clock", and continues to build AI specialized and new product capabilities. In the first half of this year, 296 branches of Meinian Health launched pancreatic tumor risk assessment products. Through the DAMO-PANDA pancreatic disease AI large model developed by Aridama Institute, the pancreas and its surrounding complex anatomical structures were automatically and accurately segmented, three-dimensional reconstruction and multi-dimensional feature extraction, so as to realize the early detection of pancreatic cancer and precancerous lesions by low-dose plain CT.

Meinian Health stated that the company will continue to deeply cultivate the B-end enterprise customer market, activate the C-end personal consumption market, and build a comprehensive growth flywheel of "breaking the circle of public domain+deepening private domain". At the same time, it will deeply layout key tracks such as longevity medicine, weight loss, dentistry, traditional Chinese medicine, and precision nutrition, accelerate the cultivation of the second curve, and explore new growth points for health management extension services. The company will actively promote the business growth of high-quality customers in industries such as government, enterprises, banks, and insurance, continuously increase the proportion of nationwide customer signings and inspection shares, and continue to actively promote efficiency reduction and innovative revenue generation based on AI and digitalization, in order to better meet the peak season of physical examinations in the second half of the year. ”

According to a research report by CITIC Securities, Meinian Health is firmly committed to implementing the "All in AI" strategy, and the effectiveness of AI empowerment has begun to show. The penetration of AI throughout the entire physical examination process will continue to improve operational efficiency and customer experience. Coupled with the deep integration of the company with platforms such as Ant Health, it will continue to expand new growth curves in the field of personal health management. "In the medium and long term, the company is upgrading from a physical examination delivery institution to an intelligent and platform based enterprise